Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Net Income (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Net Income for 11 consecutive years, with -$4.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income rose 13.81% year-over-year to -$4.2 million, compared with a TTM value of -$18.2 million through Sep 2025, up 0.91%, and an annual FY2024 reading of -$20.0 million, up 4.1% over the prior year.
  • Net Income was -$4.2 million for Q3 2025 at Lisata Therapeutics, up from -$4.7 million in the prior quarter.
  • Across five years, Net Income topped out at -$3.0 million in Q4 2023 and bottomed at -$6.2 million in Q1 2023.
  • Average Net Income over 3 years is -$4.7 million, with a median of -$4.7 million recorded in 2025.
  • The sharpest move saw Net Income tumbled 51.89% in 2024, then grew 13.81% in 2025.
  • Year by year, Net Income stood at -$3.0 million in 2023, then crashed by 51.89% to -$4.6 million in 2024, then increased by 7.83% to -$4.2 million in 2025.
  • Business Quant data shows Net Income for LSTA at -$4.2 million in Q3 2025, -$4.7 million in Q2 2025, and -$4.7 million in Q1 2025.